-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Upgrades Fulcrum Therapeutics to Outperform, Raises Price Target to $12

Benzinga·05/23/2025 12:21:17
Listen to the news
Leerink Partners analyst Joseph Schwartz upgrades Fulcrum Therapeutics (NASDAQ:FULC) from Market Perform to Outperform and raises the price target from $4 to $12.